News

MIAMI & RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--August 14, 2013-- SafeStitch Medical, Inc. (OTCBB: SFES), today announced that it has entered into a definitive agreement to merge with TransEnterix, Inc., a privately-held, medical device company with advanced technology in the use of flexible devices and robotics for minimally invasive surgery.

PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on June 26, 2013 under the symbol "ESPR." In addition, Esperion has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any.

CHICAGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced preliminary, top-line results for its DISCOVER 2 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). DISCOVER 2 results follow the recent release of data from DISCOVER 1, which also met its primary and secondary endpoints.

ATLANTA -- Nearly half of patients with a highly drug-resistant form of acute myeloid leukemia (AML) showed complete responses to a new targeted therapy called quizartinib, a researcher said here. Monotherapy with the agent led to full remission with or without complete platelet and hematologic recovery in 46% of 100 AML patients with the FMS-like tyrosine kinase 3 internal tandem duplication mutations (FLT3-ITD), said Mark Levis, MD, of Johns Hopkins University in Baltimore.

December 8, 2012 – Ithaca, NY – Advion, Inc., a leading life sciences Systems and Consumables developer, announces that its expression compact mass spectrometer (CMS) is now fully integrated with Agilent Technologies’ full range of HPLC and (U)HPLC liquid chromatography systems. The single quadropole CMS is seen as a valuable option to complement existing (U)HPLC systems.

“The approval of Quillivant XR fills a void that has long existed in the treatment of ADHD,” said Ann Childress, M.D., President of the Center for Psychiatry and Behavioral Medicine, Las Vegas, who was an investigator in the Quillivant XR laboratory classroom study. “We routinely see the struggles of patients who have difficulty swallowing pills or capsules. Having the option of a once-daily liquid will help alleviate some of these issues while still providing the proven efficacy of methylphenidate for 12 hours after dosing.”

Tokyo, Japan and San Diego, Calif., - June 4, 2012 – Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.